| scholarly article | Q13442814 |
| P356 | DOI | 10.2146/AJHP130527 |
| P698 | PubMed publication ID | 24939500 |
| P2093 | author name string | Steven D Burdette | |
| Frederick Oleson | |||
| Patrick M McDaneld | |||
| Hina N Patel | |||
| David Benziger | |||
| P2860 | cites work | A quantitative approach to membrane binding of human ubiquitous mitochondrial creatine kinase using surface plasmon resonance | Q28214232 |
| Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis | Q33576260 | ||
| In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains | Q33979251 | ||
| Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens | Q33981048 | ||
| Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vi | Q33981366 | ||
| Estrogen and gender effects on muscle damage, inflammation, and oxidative stress. | Q34011060 | ||
| Exercise-induced muscle damage and the potential protective role of estrogen | Q34511075 | ||
| Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus | Q34558111 | ||
| Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects | Q34882125 | ||
| In vivo pharmacodynamic activity of daptomycin | Q35005549 | ||
| Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers | Q35091557 | ||
| Randomized controlled trial of the safety and efficacy of Daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty | Q36364029 | ||
| Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: Cure with prolonged/high-dose daptomycin without toxicity | Q36478933 | ||
| Population pharmacokinetics of daptomycin | Q36670451 | ||
| Daptomycin: a review 4 years after first approval | Q36972980 | ||
| Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program | Q37509110 | ||
| Daptomycin: evaluation of a high-dose treatment strategy | Q37872921 | ||
| Once-daily dosing in dogs optimizes daptomycin safety | Q39537062 | ||
| Protective effect of estrogens against oxidative damage to heart and skeletal muscle in vivo and in vitro | Q40906438 | ||
| Characterization of skeletal muscle effects associated with daptomycin in rats | Q43026143 | ||
| Early experience with high-dosage daptomycin for prosthetic infections | Q43248034 | ||
| High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis | Q43443557 | ||
| Cellular adaptation to repeated eccentric exercise-induced muscle damage | Q43745444 | ||
| Functional properties of human muscle fibers after short-term resistance exercise training | Q44066846 | ||
| Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model | Q44548730 | ||
| Methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE) in a patient with Job's syndrome (hyperimmunoglobulin E syndrome) successfully treated with linezolid and high-dose daptomycin | Q44675479 | ||
| Safety analysis of high dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy. | Q44899027 | ||
| Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy. | Q45936598 | ||
| A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria | Q46459065 | ||
| Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. | Q50991026 | ||
| Relationship between exercise-induced muscle damage and enzyme release in rats | Q67792760 | ||
| Uncoupling of in vivo torque production from EMG in mouse muscles injured by eccentric contractions | Q74525973 | ||
| Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations | Q79493278 | ||
| High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study | Q84954829 | ||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1101-1107 | |
| P577 | publication date | 2014-07-01 | |
| P1433 | published in | American Journal of Health-System Pharmacy | Q15754037 |
| P1476 | title | Dosing strategy to allow continued therapy with daptomycin after asymptomatic increases in creatine kinase levels | |
| P478 | volume | 71 |
| Q45069532 | Clinical Guidance for Managing Statin and Antimicrobial Drug-Drug Interactions | cites work | P2860 |
Search more.